Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorRuijin Hospital
About this trial
In decades, the outcome of patients with peripherial T-cell lymphomas is dismal, especially in relapsed or refractory population. After failure to the frontline treatment, patients have limited treatment options and elderly population usually have no chance to undergo transplantation due to age or comorbidity, etc. Golidocitinib and chidamide were approved in treating r/r PTCL in China, while azacytidine has been demonstrated its anti-tumor activity in PTCL as well.
This study aims to explore the efficacy and safety of golidocitinib combined with azacytidine and chidamide in the patients with peripheral T-cell lymphoma who are eligible for intensive chemotherapy or transplantation.
Eligibility criteria
Qualifiers
Histopathologically confirmed peripheral T-cell lymphoma;
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2;
Expected survival of ≥12 weeks;
Measurable disease lesions;
Disqualifiers
Involvement of the central nervous system (CNS);
History of malignancies except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix;
Uncontrolled cardio- and cerebro-vascular disease, blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases
Left ventricular ejection fraction<50%
Trial design
Treatments tested in this trial
- golidocitinib with azacytidine and chidamide
Treatment groups
30 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov